Captor Therapeutics Spolka Akcyjna (CAPTORTX) aktie

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that using the Optigrade drug discovery platform overcomes the limitations of inhibitors and antibody drugs by destroying disease causing proteins resistant to available therapeutics. Its products in various stages of development include CT-01, which also completed the Phase 1 clinical trials for the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor; and CT-03, which has completed the Phase 1 clinical trials for the treatment of small cell lung cancer, non-small cell lung cancer, and triple-negative breast cancer intervention in multiple severe malignancies. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland.